|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0332293,
umls-concept:C0600688,
umls-concept:C0681842,
umls-concept:C0796639,
umls-concept:C0871261,
umls-concept:C1421331,
umls-concept:C1421333,
umls-concept:C1516213,
umls-concept:C1527249,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-2-14
|
|
pubmed:abstractText |
Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC). We hypothesized that germline polymorphisms within genes related to drug target (thymidylate synthase) or metabolizing enzymes (UDP-glucuronosyltransferase, UGT) would impact response and toxicity to the combination of capecitabine plus irinotecan (CPT-11).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1226-36
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15709193-Adult,
pubmed-meshheading:15709193-Aged,
pubmed-meshheading:15709193-Aged, 80 and over,
pubmed-meshheading:15709193-Alleles,
pubmed-meshheading:15709193-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15709193-Camptothecin,
pubmed-meshheading:15709193-Colorectal Neoplasms,
pubmed-meshheading:15709193-Deoxycytidine,
pubmed-meshheading:15709193-Diarrhea,
pubmed-meshheading:15709193-Female,
pubmed-meshheading:15709193-Fluorouracil,
pubmed-meshheading:15709193-Gene Frequency,
pubmed-meshheading:15709193-Genotype,
pubmed-meshheading:15709193-Germ-Line Mutation,
pubmed-meshheading:15709193-Glucuronosyltransferase,
pubmed-meshheading:15709193-Haplotypes,
pubmed-meshheading:15709193-Humans,
pubmed-meshheading:15709193-Linkage Disequilibrium,
pubmed-meshheading:15709193-Male,
pubmed-meshheading:15709193-Middle Aged,
pubmed-meshheading:15709193-Neoplasm Metastasis,
pubmed-meshheading:15709193-Neutropenia,
pubmed-meshheading:15709193-Polymorphism, Genetic,
pubmed-meshheading:15709193-Prognosis,
pubmed-meshheading:15709193-Prospective Studies,
pubmed-meshheading:15709193-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
|
|
pubmed:affiliation |
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
